MRModerna MRNA · NASDAQ
$226.30 +4.65% (+$10.05)
- Market cap
- $89.8B
- Enterprise value
- $89.4B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 40.3x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -40.0%
- Bruto marža
- -12.6%
- Neto marža
- -141.4%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 0.90
- Free float
- 93.2%
O podjetju
Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.
Sector
Healthcare
Industry
Biotechnology
CEO
Stéphane Bancel
Employees
4,700
Headquarters
Cambridge
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke